Abstract
Background: The need to develop premotor PD biomarkers is increasingly apparent as early detection of Parkinson's disease (PD) in the premotor stage, which includes some non-motor symptoms, will help patients benefit from potential neuroprotective treatments.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
